About the API
Edoxaban is an anti-clotting substance indicated to reduce the risk of stroke and systemic embolism (blood coagulation) in patients with nonvalvular atrial fibrillation (abnormal heart rhythm that is not caused by a heart valve problem).
Atrial fibrillation occurs when the heart’s two upper chambers (atria) do not contract properly, allowing formation of blood clots, which can travel to other parts of the body. Blood clots may cause stroke, heart attacks, and severe problems in other parts of the body.
Edoxaban tosylate monohydrate has also been approved for the treatment of deep vein thrombosis and pulmonary embolism in patients who have already been treated with an anti-clotting drug administered by injectable or infusion (parenterally), for five to ten days.
Edoxaban was developed by Tokyo-based Daiichi Sankyo Company. It was approved in Japan in 2011, and in the United States and the EU in 2015. It is prepared through multi-step chemical synthesis.